Screener / SEC EDGAR /CIK 0001759425 /10-K filed Feb 25, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Mirum Pharmaceuticals, Inc. MIRM

Compare with peers Embed
FY2025 at a glance

Sales up 54.7%, free cash flow up to $54.9M

XBRL, from each 10-K
RevenueStatements
$521.3M from $336.9M in FY2024
FY2019FY2025
Net incomeStatements
-$23.4M from -$87.9M in FY2024
FY2019FY2025
Free cash flowStatements
$54.9M from $9.3M in FY2024
FY2019FY2025
EPS (diluted)Statements
$-0.47 from $-1.85 in FY2024
FY2019FY2025
Operating marginStatements
-4.2% from -26.0% in FY2024
FY2019FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (34)
EPS (ttm)
-14.47
Sales (ttm)
670.8M
Net income (ttm)
-903.9M
Sales growth
+54.7%
EPS growth
-
Sales Q/Q
+39.6%
Free cash flow
-273.9M
Gross margin
-
Oper. margin
-133.6%
Net margin
-134.8%
FCF margin
-40.8%
ROE
n/m
R&D / sales
35.7%
Dividend
-
Debt/Eq
n/m
Curr. ratio
2.07
Cash
243.2M
Op. cash flow (ttm)
-271.3M
EBITDA
2.1M
EBITDA margin
0.4%
Quick ratio
1.98
Interest cover
-1.54
FCF after stock pay
-16.6M
Oper. margin low 5y
-906.1%
Stock pay / sales
13.7%
Shares out.
65.3M
Shares Y/Y
+5.6%
Book / share
-0.83
Cash / share
3.73
Sales / share
10.28
Asset turnover
0.65
Days sales out.
86
Sales 3Y CAGR
+89.1%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2020 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 521.3M Net income -23.4M
FY2020 revenue 0 · Revenues, 0000950170-22-003229 FY2020 net income -103.3M · NetIncomeLoss, 0000950170-22-003229 0 FY2020 FY2021 revenue 19.1M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-24-032289 FY2021 net income -84.0M · NetIncomeLoss, 0000950170-24-032289 19.1M FY2021 FY2022 revenue 77.1M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001759425-25-000014 FY2022 net income -135.7M · NetIncomeLoss, 0001759425-25-000014 77.1M FY2022 FY2023 revenue 186.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001759425-26-000013 FY2023 net income -163.4M · NetIncomeLoss, 0001759425-26-000013 186.4M FY2023 FY2024 revenue 336.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001759425-26-000013 FY2024 net income -87.9M · NetIncomeLoss, 0001759425-26-000013 336.9M FY2024 FY2025 revenue 521.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001759425-26-000013 FY2025 net income -23.4M · NetIncomeLoss, 0001759425-26-000013 521.3M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing.

Growth per share, FY2019 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +12.1% a year FY2021 $3.96 to FY2025 $6.27, 4 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$0.47$6.27$1.09
Dec 31, 2024 -$1.85$4.75$0.20
Dec 31, 2023 -$4.00$6.08-$1.74
Dec 31, 2022 -$4.02$4.18-$3.54
Dec 31, 2021 -$2.77$3.96-$4.38
Dec 31, 2020 ---
Dec 31, 2019 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $549.7M
  • − All liabilities $528.1M
  • = Net current asset value $21.6M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $314.7M
  • − Other intangible assets $260.9M
  • = Tangible book value $53.8M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

MIRM against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+54.7%15th of 155 · median +10.5%
Net margin
-4.1%15.3%
-134.8%146th of 154 · median 6.8%
Free cash flow margin
2.3%19.2%
-40.8%131st of 145 · median 10.0%
MIRM and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
MIRM Mirum Pharmaceuticals, Inc.$670.8M +54.7%--134.8%--40.8%-
RARE Ultragenyx Pharmaceutical Inc.$730.0M +20.2%--71.8%--60.5%-
TMDX TransMedics Group, Inc.$727.6M +37.1%58.6%19.9%26.2%6.1%-
GKOS GLAUKOS Corp$690.3M +32.3%64.8%-24.6%-23.7%5.2%-
TARS Tarsus Pharmaceuticals, Inc.$682.2M +147%--102.9%-4.8%0.70
UFPT UFP Technologies Inc$649.5M +19.5%28.9%11.8%15.8%-0.20
All 162 companies in the group

Where the $521.3M of revenue came from

by product, year to Dec 31, 2025

  • Livmarli $360.0M · 69%
  • Bile Acid Medicines $161.3M · 31%

From the segment tables in the 10-K XBRL.

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2021 · 10-K XBRL, year-end balances

Return on equity -7.4% FY2021: -69.9% net income ÷ equity
Net margin -4.5% FY2021: -438.9% profit per $ of sales: -23.4M ÷ 521.3M
Asset turnover 0.62× FY2021: 0.06× sales per $ of assets: 521.3M ÷ 842.8M
Leverage 2.68× FY2021: 2.45× assets per $ of equity: 842.8M ÷ 314.7M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -134.8% vs 6.8%
  • A profit in 0 of 6 years
Net margin, FY2020 to FY2025: -438.9% to -4.5%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -1.5× interest expense
  • Current assets cover current liabilities
    Current ratio 2.07

Cash and shareholders

  • Free cash flow positive in 2 of 6 years
    $54.9M last year
  • Share count up over 4 years
    +65.6%
Free cash flow, FY2020 to FY2025: -89.3M to 54.9M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

MIRM's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 7. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue521.3M
FY2019: -FY2020: 0FY2021: 19.1MFY2022: 77.1MFY2023: 186.4MFY2024: 336.9MFY2025: 521.3M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income-23.4M
FY2019: -52.6MFY2020: -103.3MFY2021: -84.0MFY2022: -135.7MFY2023: -163.4MFY2024: -87.9MFY2025: -23.4M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow54.9M
FY2019: -39.6MFY2020: -89.3MFY2021: -132.8MFY2022: -120.4MFY2023: -71.1MFY2024: 9.3MFY2025: 54.9M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow after stock pay-16.6M
FY2019: -45.7MFY2020: -101.9MFY2021: -155.9MFY2022: -147.4MFY2023: -106.1MFY2024: -39.1MFY2025: -16.6M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
EPS (diluted)-0.47
FY2019: -4.58FY2020: -4.09FY2021: -2.77FY2022: -4.02FY2023: -4.00FY2024: -1.85FY2025: -0.47 FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Diluted shares50.2M
FY2019: -FY2020: -FY2021: 30.3MFY2022: 34.0MFY2023: 40.9MFY2024: 47.5MFY2025: 50.2M FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Livmarli 360.0M69.1% +68.8%
Bile Acid Medicines 161.3M30.9% +31.0%
License and other revenue 00.0% -100%

10-K 0001759425-26-000013, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue-019.1M77.1M186.4M336.9M521.3M
R&D43.0M81.6M131.4M106.8M102.6M140.6M186.2M
SG&A11.8M22.7M59.2M89.1M145.9M202.2M257.0M
Operating income-54.7M-104.3M-173.4M-131.2M-109.2M-87.6M-22.1M
Interest expense--016.0M15.1M14.3M14.4M
Pretax income-52.5M-103.3M-84.0M-142.1M-162.4M-86.9M-21.4M
Income tax21K6K37K-6.4M991K1.0M1.9M
Net income-52.6M-103.3M-84.0M-135.7M-163.4M-87.9M-23.4M
EPS (diluted)-4.58-4.09-2.77-4.02-4.00-1.85-0.47
Diluted shares--30.3M34.0M40.9M47.5M50.2M
Depreciation & amortization139K305K595K3.2M10.8M23.6M24.2M
EBITDA-54.6M-104.0M-172.8M-128.0M-98.3M-64.0M2.1M
Operating margin---906.1%-170.3%-58.6%-26.0%-4.2%
Net margin---438.9%-176.0%-87.7%-26.1%-4.5%
Revenue growth---+303%+142%+80.8%+54.7%

Cash flow

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-39.4M-89.1M-132.8M-120.1M-70.9M10.3M55.8M
Capital spending281K225K24K278K109K993K954K
Free cash flow-39.6M-89.3M-132.8M-120.4M-71.1M9.3M54.9M
Stock-based pay (added back)6.1M12.6M23.1M27.0M35.0M48.4M71.4M
Free cash flow after stock pay-45.7M-101.9M-155.9M-147.4M-106.1M-39.1M-16.6M
Acquisitions--00212.8M00
Investing cash flow-127.8M37.9M48.5M7.7M-107.2M-90.1M-24.0M
Financing cash flow127.2M181.3M73.5M109.1M336.6M17.7M40.1M

Stock-based pay and leases

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)6.1M12.6M23.1M27.0M35.0M48.4M71.4M
Stock-based pay / revenue--120.6%35.0%18.8%14.4%13.7%
Operating lease cash paid170K576K864K911K1.1M1.3M2.6M
Right-of-use assets2.4M1.9M1.6M1.4M1.3M8.7M8.7M
Operating lease liabilities3.6M3.3M2.6M2.2M1.7M9.7M9.7M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MIRM/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.